Literature DB >> 26830300

White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink.

Jason M Glanz1, Sophia R Newcomer2, Michael L Jackson3, Saad B Omer4, Robert A Bednarczyk5, Jo Ann Shoup2, Frank DeStefano6, Matthew F Daley7.   

Abstract

While the large majority of parents in the U.S. vaccinate their children according to the recommended immunization schedule, some parents have refused or delayed vaccinating, often citing safety concerns. In response to public concern, the U.S. Institute of Medicine (IOM) evaluated existing research regarding the safety of the recommended immunization schedule. The IOM concluded that although available evidence strongly supported the safety of the currently recommended schedule as a whole, additional observational research was warranted to compare health outcomes between fully vaccinated children and those on a delayed or alternative schedule. In addition, the IOM identified the Vaccine Safety Datalink (VSD) as an important resource for conducting this research. Guided by the IOM findings, the Centers for Disease Control and Prevention (CDC) commissioned a White Paper to assess how the VSD could be used to study the safety of the childhood immunization schedule. Guided by subject matter expert engagement, the resulting White Paper outlines a 4 stage approach for identifying exposure groups of undervaccinated children, presents a list of health outcomes of highest priority to examine in this context, and describes various study designs and statistical methods that could be used to analyze the safety of the schedule. While it appears feasible to study the safety of the recommended immunization schedule in settings such as the VSD, these studies will be inherently complex, and as with all observational studies, will need to carefully address issues of confounding and bias. In light of these considerations, decisions about conducting studies of the safety of the schedule will also need to assess epidemiological evidence of potential adverse events that could be related to the schedule, the biological plausibility of an association between an adverse event and the schedule, and public concern about the safety of the schedule.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alternative immunization schedule; Parental vaccine concerns; Parental vaccine refusal; Recommended immunization schedule; Vaccine safety; Vaccine safety methods

Mesh:

Substances:

Year:  2016        PMID: 26830300     DOI: 10.1016/j.vaccine.2015.10.082

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  A primer on quantitative bias analysis with positive predictive values in research using electronic health data.

Authors:  Sophia R Newcomer; Stan Xu; Martin Kulldorff; Matthew F Daley; Bruce Fireman; Jason M Glanz
Journal:  J Am Med Inform Assoc       Date:  2019-12-01       Impact factor: 4.497

2.  The use of natural language processing to identify Tdap-related local reactions at five health care systems in the Vaccine Safety Datalink.

Authors:  Chengyi Zheng; Wei Yu; Fagen Xie; Wansu Chen; Cheryl Mercado; Lina S Sy; Lei Qian; Sungching Glenn; Gina Lee; Hung Fu Tseng; Jonathan Duffy; Lisa A Jackson; Matthew F Daley; Brad Crane; Huong Q McLean; Steven J Jacobsen
Journal:  Int J Med Inform       Date:  2019-04-13       Impact factor: 4.046

3.  Undervaccination with diphtheria, tetanus, and pertussis vaccine: National trends and association with pertussis risk in young children.

Authors:  Wan-Ting Huang; Hui-Chen Lin; Chin-Hui Yang
Journal:  Hum Vaccin Immunother       Date:  2016-11-18       Impact factor: 3.452

4.  Bias from outcome misclassification in immunization schedule safety research.

Authors:  Sophia R Newcomer; Martin Kulldorff; Stan Xu; Matthew F Daley; Bruce Fireman; Edwin Lewis; Jason M Glanz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-01-02       Impact factor: 2.890

5.  Methods for addressing "innocent bystanders" when evaluating safety of concomitant vaccines.

Authors:  Shirley V Wang; Abdurrahman Abdurrob; Julia Spoendlin; Edwin Lewis; Sophia R Newcomer; Bruce Fireman; Matthew F Daley; Jason M Glanz; Jonathan Duffy; Eric S Weintraub; Martin Kulldorff
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-13       Impact factor: 2.890

6.  Use of three summary measures of pediatric vaccination for studying the safety of the childhood immunization schedule.

Authors:  Stanley Xu; Sophia R Newcomer; Martin Kulldorff; Matthew F Daley; Bruce Fireman; Jason M Glanz
Journal:  Vaccine       Date:  2019-01-29       Impact factor: 3.641

7.  Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule.

Authors:  Matthew F Daley; Jason M Glanz; Sophia R Newcomer; Michael L Jackson; Holly C Groom; Marlene M Lugg; Huong Q McLean; Nicola P Klein; Eric S Weintraub; Michael M McNeil
Journal:  Vaccine       Date:  2017-03-09       Impact factor: 3.641

8.  Analyzing self-controlled case series data when case confirmation rates are estimated from an internal validation sample.

Authors:  Stanley Xu; Christina L Clarke; Sophia R Newcomer; Matthew F Daley; Jason M Glanz
Journal:  Biom J       Date:  2018-05-16       Impact factor: 2.207

9.  Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule.

Authors:  Matthew F Daley; Jo Ann Shoup; Sophia R Newcomer; Michael L Jackson; Holly C Groom; Steven J Jacobsen; Huong Q McLean; Nicola P Klein; Eric S Weintraub; Michael M McNeil; Jason M Glanz
Journal:  Acad Pediatr       Date:  2018-03-28       Impact factor: 3.107

Review 10.  Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions.

Authors:  Caitlin Dodd; Nick Andrews; Helen Petousis-Harris; Miriam Sturkenboom; Saad B Omer; Steven Black
Journal:  BMJ Glob Health       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.